Here are four highlights:
Inflectra is administered by IV infusion and is indicated for:
- Adults and children (aged six years and older) with moderate to severe Crohn’s disease who have had an inadequate response to conventional therapy
- Adults with moderate to severe ulcerative colitis who have had an inadequate response to conventional therapy
- Patients with moderate to severe rheumatoid arthritis, in combination with methotrexate
- Patients with active ankylosing spondylitis
- Patients with active psoriatic arthritis
- Adults with chronic severe plaque psoriasis
2. The FDA approval was based on the comprehensive data package submitted by Celltrion, a biopharmaceutical company based in Incheon, South Korea, demonstrating a high degree of similarity between Inflectra and the U.S. reference product, Remicade.
3. The most common expected side effects of Inflectra include respiratory infections, such as sinus infections and sore throat, headache, coughing and stomach pain.
4. Remicade received FDA approval in 1998.
More articles on GI & endoscopy:
Digestive Health Specialists, SonarMD partner: 3 points
Health Care Service Corporation issues coverage policy for Torax Medical’s LINX system: 4 notes
Allergan CEO: US target on Pfizer, Allergan merger was ‘un-American’ — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
